The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.
September 19th 2023
The FDA has granted priority review to the supplemental new drug application seeking the approval of belzutifan for the treatment of previously treated patients with advanced renal cell carcinoma following immune checkpoint and anti-angiogenic therapies.
25th Annual International Lung Cancer Congress®
Register Now!
BURST CME™: Utilizing Pathology Reports to Inform Treatment Plans Across GI Cancers
View More
Bridging the Care Gap in Anemia in CKD: A Comprehensive Guide to Enhancing Patient Care
Register Now!
2022 BURST Year in Review™: Reflecting on Recent Evidence for Testing in Patients with GI Cancers
View More
2nd Annual International Congress on Pediatric Oncology
View More
2022 BURST Year in Review™: How Has Recent Evidence in Testing Elevated Outcomes in Patients with Lung Cancers
View More
Community Practice Connections™: 23rd Annual International Lung Cancer Congress®
View More
How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities
Register Now!
PER's Breast Cancer Symposia in San Antonio
Register Now!
2023 Friday Satellite Symposia: Preceding the 65th ASH Annual Meeting and Exposition
Register Now!
Oncology Town Hall™: Primary Investigators Present Key Abstracts in Genitourinary Malignancies from Paris
View More
BURST CME™: Addressing Current Standards and Unmet Needs in Patients with Metastatic Breast Cancer
View More
Clinical Vignettes: 40th Annual CFS®: Innovative Cancer Therapy for Tomorrow®
View More
20th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
View More
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
9th Annual School of Gastrointestinal Oncology® (SOGO®)
Register Now!
Expert Perspectives on Emerging CDK4/6 Inhibitor Strategies in Advanced Prostate Cancer Management Settings
View More
New York GU 17th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies
Register Now!
New Targets, New Treatments, and New Combinations for the Management of Advanced Prostate Cancer
View More
BURST CME™: What Is the Real Risk in Lower-Risk MDS?
View More
BURST CME™: How Does Transfusion Burden Impact Real-World Outcomes in MDS?
View More
BURST CME™: Understanding Transfusion Dependence in Lower-Risk MDS
View More
Medical Crossfire®: Why is PSMA so Effective? To Affinity and Beyond
View More
Advances In™ KRAS Inhibition: Modern Considerations In Targeting KRAS-Mutated Lung, Colorectal, And Pancreatic Cancers
View More
How We Do It™: Integrating Gene Fusion Testing in Oncology Clinics for Patients with NSCLC
View More
A Focus on Acute Myeloid Leukemia
View More
Updates in Myelodysplastic Syndromes
View More
The Latest on Acute Lymphocytic Leukemia
View More
Medical Crossfire®: Key Strategies to Prioritize Testing and the Evolving Role of Genomic Alterations in Providing Precision NSCLC Care
View More
Community Practice Connections™: The Newest Frontier in HR+ Breast Cancer—Targeting ESR1 Mutations with Next-Generation Endocrine Therapy
View More
Molecular Subtyping and Surgical Sequencing Broaden Immunotherapy Applications in RCC
August 14th 2023Tian Zhang, MD, discusses unanswered questions regarding molecular drivers of kidney cancer that the OPTIC RCC trial aims to answer, next steps with this research, and the potential benefits of receiving systemic therapy prior to undergoing cytoreductive nephrectomy for patients with metastatic renal cell carcinoma.
Evaluation of Novel Agents and Combinations Aims to Improve Outcomes in Frontline RCC
Ulka Nitin Vaishampayan, MBBS, discusses factors to consider for choosing between immuno-oncology/immuno-oncology and VEGF TKI/immuno-oncology combinations for the frontline treatment of patients with renal cell carcinoma, areas of ongoing research in this disease, and treatment updates across the prostate cancer spectrum.
SAMETA Trial Evaluates Efficacy of Savolitinib Plus Durvalumab in MET-Driven Papillary RCC
August 10th 2023The safety and efficacy achieved with the combination of savolitinib and durvalumab vs standard-of-care sunitinib or durvalumab monotherapy will be evaluated in patients with MET-driven papillary renal cell carcinoma in the phase 3 SAMETA trial.
Stereotactic Radiation Strategies May Bolster RCC Multi-Modality Management Efforts
August 3rd 2023Raquibul Hannan, MD, PhD, discusses the benefits of using stereotactic radiation in patients with localized RCC who are unfit for surgery, research findings indicating improved outcomes in patients who received radiation for metastatic disease, and how this radiation technique may work in concert with systemic therapy.
Investigators Pursue the Role of the Microbiome on Immunotherapy Treatment in RCC
Pedro C. Barata, MD, MSc, discusses the importance of further exploring the facets of manipulating the microbiome to augment responses with immunotherapy in RCC, as well as the promise of the bifidogenic live bacterial product, CBM588.
Rini Expands on Key Clinical Trial Updates in GU Cancers from the 2023 ASCO Annual Meeting
Brian I. Rini, MD, FASCO, highlights key clinical trial updates from the genitourinary cancers landscape presented at the 2023 ASCO Annual Meeting, details the implications of the CONTACT-03 data, expands on the long-term data from the phase 3 KEYNOTE-426 trial in clear cell RCC, discusses findings from the phase 3 TALAPRO-2 trial in patients with metastatic castration-resistant prostate cancer, and more.
Dr Ged on the Background of the ORCHID Trial in BAP1-Mutated Metastatic RCC
July 18th 2023Yasser Mohamed Ali Ged, MBBS, discusses the background of launching the phase 2 ORCHID trial evaluating olaparib monotherapy in patients with metastatic renal cell carcinoma harboring BAP1 or other DNA repair gene mutations.
Dr Basin on the Methods for Investigating Hsp70 Inhibition in Belzutifan-resistant in RCC
July 14th 2023Michael Basin, MD, discusses the design of a preclinical investigation into the pharmacological inhibition of the molecular chaperone Hsp70 and how it relates to belzutifan resistance in clear cell renal cell carcinoma.
Tumor Sequencing Identifies Host Signatures Tied to Immunotherapy Response in Advanced RCC
July 14th 2023Higher levels of baseline TCR clonality in peripheral blood mononuclear cells (PBMCs) and baseline IgG1 fraction in PBMCs and tumor tissue were identified in an institutional cohort of samples from patient with metastatic renal cell carcinoma.
Olaparib Monotherapy Showcases Antitumor Activity in BAP1-mutated RCC
Olaparib monotherapy elicited responses with favorable tolerability in patients with renal cell carcinoma whose tumors harbored BAP1 or other DNA repair gene mutations, according to data from the interim analysis of the phase 2 ORCHID trial presented during the 2023 Kidney Cancer Research Summit.
Knowledge Gap Remains for Sequencing of Later-Line Treatments of Advanced RCC
Although the use of immunotherapy treatment approaches continues to become more prevalent in advanced renal cell carcinoma, high-level evidence showing benefit of sequential administration of these agents are limited.
Dr Lee on Extended Follow-Up With Pembrolizumab and Lenvatinib in Pretreated mRCC
July 14th 2023Chung-Han Lee, MD, PhD, discusses the final results of the phase 2 cohort of a phase 1/2 trial evaluating lenvatinib plus pembrolizumab in patients with pretreated metastatic clear cell renal cell carcinoma.
Adjuvant Pembrolizumab Provides Survival Benefit Across ccRCC Risk Groups and Disease Stages
Adjuvant pembrolizumab prolonged disease-free survival and distant metastasis-free survival compared with placebo across The University of California Los Angeles Integrated Staging System–categorized subgroups of patients with clear cell renal cell carcinoma.